openPR Logo
Press release

Recent Research: Detailed Analysis on Biosimilar Pipeline Analysis Market Size with Forecast to 2026 - Biocon, Pfizer Inc., F. Hoffmann-La Roche Ltd, Amgen Inc

07-27-2019 10:06 AM CET | Health & Medicine

Press release from: Coherent Market Insights (CMI)

Biosimilar Pipeline Analysis

Biosimilar Pipeline Analysis

Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness among people are expected to fuel the growth of biosimilar pipeline market.

Request Free Sample of Report: @ www.coherentmarketinsights.com/insight/request-sample/582

Various companies and their R&D departments such as Pfizer Inc., Zydus Cadila are involved in the development of biosimilar, which is under clinical trial. Pfizer’s biosimilar clinical stage pipeline includes five monoclonal antibodies fare under clinical trial phase I and phase 3 which will be used for the treatment of autoimmune disease and oncology.

There are various patented drugs available in the market, with certain drugs such as Adalimumab, the high cost of these drugs directed the biosimilar market. There are few drugs, which are under the last phase of clinical trial are BI695502 developed by Boehringer Ingelheim, PF- 06439535 by Pfizer, Biosimilar bevacizumab by Biocon, and FKB238 by Kyowa Pharmaceutical Industry Co. Increased R&D is expected to support the growth of biosimilar pipeline analysis market. There is a need for complex infrastructure in the development of biosimilar and lengthy process of clinical trial and approval are the major challenges faced by biosimilar pipeline analysis market.

Get Discount for This Report at https://www.coherentmarketinsights.com/insight/request-discount/582

Biosimilar pipeline analysis market taxonomy:

By Product Type

Human Growth Hormone
Insulin
Interferon
Peptides
Monoclonal antibodies
Others
By Services

Clinical Trials
Contract Research and Manufacturing
By Technology

Electrophoresis
Recombinant DNA Technology
Chromatography
Nuclear Magnetic Resonance Technology
Bioassay
Mass Spectrometry
Western Blotting
By Application

Oncology Disease
Auto immune Disease
Blood Disease
Growth Hormone Deficiencies

There are various players present across the world and competing with each other extensively in the market to attain maximum share. Companies are also involved in R&D to increase the biosimilar pipeline. Some key players are Biocon, Pfizer Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca, Novartis AG, and Merck & Co.

Purchase Copy of This Report: www.coherentmarketinsights.com/insight/buy-now/582

Abhout US

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Recent Research: Detailed Analysis on Biosimilar Pipeline Analysis Market Size with Forecast to 2026 - Biocon, Pfizer Inc., F. Hoffmann-La Roche Ltd, Amgen Inc here

News-ID: 1812787 • Views:

More Releases from Coherent Market Insights (CMI)

Huge Growth in Mobile Imaging Services Market 2023 to see Future Opportunities 2030 | Carestream Health, Accurate Imaging, Inc., Alliance HealthCare Services
Huge Growth in Mobile Imaging Services Market 2023 to see Future Opportunities 2 …
𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄: Mobile imaging services are provided by trained professionals who are equipped with state-of-the-art imaging technology that can be transported and set up on location. The images obtained through mobile imaging services are then transmitted electronically to the patient's healthcare provider for analysis and diagnosis. Mobile imaging services are used in a variety of healthcare settings, including hospitals, clinics, nursing homes, and home health agencies. They are particularly useful for imaging patients
Huge Growth in Particle Therapy Market 2023 to see Future Opportunities 2030 | Ion Beam Applications, Provision Healthcare, Mevion Medical Systems
Huge Growth in Particle Therapy Market 2023 to see Future Opportunities 2030 | I …
Coherent Market Insight has published a new research report titled "Particle Therapy Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns, revenue forecasts, and
Digital Mobile X Ray Devices Market 2023 to see Future Opportunities 2030 | Toshiba Corporation, Carestream Health, General Electric Company
Digital Mobile X Ray Devices Market 2023 to see Future Opportunities 2030 | Tosh …
Coherent Market Insight has published a new research report titled "Digital Mobile X Ray Devices Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns,
Huge Growth in Chemiluminescence Imaging Market 2023 to see Future Opportunities 2030 | LI-COR Biosciences, Analytik Jena US, Azure Biosystems, Berthold Technologies GmbH & Co. KG
Huge Growth in Chemiluminescence Imaging Market 2023 to see Future Opportunities …
Coherent Market Insight has published a new research report titled "Chemiluminescence Imaging Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns, revenue forecasts, and

All 5 Releases


More Releases for Biosimilar

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.